[Enhancing active immunity against hepatitis B virus by HBV vaccine immunization in patients with HBV-related end-stage liver diseases treated with liver transplantation].
OBJECTIVE
To study the active immunity response of liver transplant patients for HBV-related diseases after hepatitis B virus (HBV) vaccine immunization and to investigate the factors that influence the effectiveness of the vaccination in order to find measures to increase its success.


METHODS
Thirteen patients who had liver transplants because of HBV-related end-stage liver diseases received hepatitis B virus immunoglobulin and lamivudine for an average of 38 months (range 27-77 months). They received double intramuscular doses (40 microg) of a recombinant vaccine at months 0, 1, 2 and 6. The anti-HBs titers were tested regularly at months 1, 2, 3, 6 and 7.


RESULTS
Seven of the 13 patients (53.8%) developed higher serum titers of anti-HBs compared with their titers prior to the vaccinations, 2 patients of the 13 (15.4%) developed an increase by 100 U/L and in 4 patients (30.8%) their base levels were doubled. Those responding patients were followed-up for another 8 months after the fourth vaccination, and only 1 patient among them had a decrease of the anti-HBs titers below the level prior to the vaccination.


CONCLUSIONS
Hepatitis B vaccine immunization can be used to enhance the active immunity against HBV in patients who had liver transplants for HBV-related diseases.
Jin
Sheng-jie
SJ
General Surgery Department, West China Hospital of Sichuan University, Chengdu 610041,China.
Lu
Shi-chun
SC
Lai
Wei
W
Dai
Jun
J
Zhao
Ji
J
Li
You-ping
YP
Yan
Lü-nan
LN
D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006515:Hepatitis B virus; D006801:Humans; D007110:Immunity, Active; D008107:Liver Diseases / Q000276:immunology* / Q000821:virology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period
D017325:Hepatitis B Vaccines